Evidence map›Paper›PMID 42792682›Full record

ArticleBiomedicines2026

BUB1 and CDK4/6 Dual Inhibition Increases Radiation Sensitivity in Glioblastoma, Lung Cancer, and Triple-Negative Breast Cancer.

Shivani Thoidingjam, Sushmitha Sriramulu, Asya Haider Muratoglu, Rhea Hede-Sakhardande, Sunita Ghosh, Anthony J Davis, Stephen L Brown, Farzan Siddiqui, Benjamin Movsas, Corey Speers and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shivani ThoidingjamDepartment of Radiation Oncology, Henry Ford Health-Cancer, Detroit, MI 48202, USA.
Sushmitha SriramuluDepartment of Radiation Oncology, Henry Ford Health-Cancer, Detroit, MI 48202, USA.
Asya Haider MuratogluDepartment of Radiation Oncology, Henry Ford Health-Cancer, Detroit, MI 48202, USA.ORCID 0009-0002-0048-4765
Rhea Hede-SakhardandeDepartment of Radiation Oncology, Henry Ford Health-Cancer, Detroit, MI 48202, USA.
Sunita GhoshDepartment of Public Health Sciences, Henry Ford Health, Detroit, MI 48202, USA.
Anthony J DavisDepartment of Radiation Oncology, University of Texas Southwestern, Dallas, TX 75390, USA.
Stephen L BrownDepartment of Radiation Oncology, Henry Ford Health-Cancer, Detroit, MI 48202, USA.
Farzan SiddiquiDepartment of Radiation Oncology, Henry Ford Health-Cancer, Detroit, MI 48202, USA.
Benjamin MovsasDepartment of Radiation Oncology, Henry Ford Health-Cancer, Detroit, MI 48202, USA.
Corey SpeersDepartment of Radiation Oncology, University of Alabama, Birmingham, AL 35233, USA.
Shyam NyatiDepartment of Radiation Oncology, Henry Ford Health-Cancer, Detroit, MI 48202, USA.ORCID 0000-0002-1435-303X

Funding

Henry Ford Health System
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BUB1CDK4/6DNA repairHRNHEJradiotherapy

Identifiers

PMID42792682
PMCPMC13604186

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.